Archived Content

 

Recently published papers from the PEGS Europe speakers 

 

Short Course Instructors 

 

Tudor Arvinte, Ph.D., CEO, Therapeomic, Inc.; Professor, University of Geneva  

  • Aggregation of biopharmaceuticals in human plasma and human serum: Implications for drug research and development View Paper 
  • New methods allowing the detection of protein aggregates: A case study on trastuzumab View Paper 
  • Addressing new analytical challenges in protein formulation development View Paper 

Jonas V. Schaefer, Ph.D., High-Throughput Laboratory, Biochemistry, University of Zurich   

  • Engineering Aggregation Resistance in IgG by Two Independent Mechanisms: Lessons from Comparison of Pichia Pastoris and Mammalian Cell Expression View Paper 
  • Transfer of Engineered Biophysical Properties between Different Antibody Formats and Expression Systems View Paper 

 Arne Skerra, Ph.D., Professor, Chair of Biological Chemistry, Technical University  

  • PASylation: a biological alternative to PEGylation for extending the plasma-half life of pharmaceutically active proteins View Paper 
  • High-yield production of PASylated human growth hormone using secretory E. coli technology View Paper 

Novel Antibody Constructs and Alternative Scaffolds  

 

Arne Skerra, Ph.D., Professor, Chair of Biological Chemistry, Technical University  

  • Anticalins: an emerging class of novel biologics to treat cancer and other severe diseases View Paper  
  • Combinatorial design of an Anticalin directed against the extra-domain B for the specific targeting of oncofetal fibronectin View Paper  

Janine Schuurman, Ph.D., Director, Strategic Research, Genmab B.V.  

  • Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange View Paper  

Johan Nilvebrant, Ph.D., Post-Doctoral Researcher, Protein Technology, Royal Institute of Technology, Alba Nova University Center  

  • Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3 View Paper  
  • Selection and in vitro characterization of human CD44v6-binding antibody fragments View Paper  
  • Engineering bispecificity into a single albumin-binding domain View Paper  

Ulrich Brinkmann, Ph.D., Senior Principal Scientist, Pharma Research and Early Development (pRED), Large Molecule Research, Roche Penzberg  

  • The Intriguing Options of Multispecific Antibody Formats for Treatment of Cancer View Paper  
  • Targeted siRNA Delivery and mRNA Knockdown Mediated by Bispecific Digoxigenin-binding Antibodies View Paper 
  • Bispecific Antibody Derivatives with Restricted Binding Functionalities that are Activated by Proteolytic Processing View Paper  
  • Progress in Overcoming the Chain Association issue in Bispecific Heterodimeric IgG Antibodies View Paper 
  • Bispecific Antibody Derivatives Based on Full-Length IgG Formats View Paper  
  • Development of Tetravalent IgG1 Dual Targeting IGF-1R-EGFR Antibodies with Potent Tumor Inhibition View Paper  
  • Human-Protein-Derived Peptides for Intracellular Delivery of Biomolecules View Paper  
  • A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors View Paper  
  • Genetically Engineered Fusion Proteins for Treatment of Cancer View Paper  
  • Generation Of Fluorescent IgG Fusion Proteins in Mammalian Cells View Paper  
  • Fully Human Targeted Cytotoxic Fusion Proteins: New Anticancer Agents on the Horizon View Paper  

Cancer Biotherapeutics  

 

Germaine Fuh, Ph.D., Senior Scientist, Antibody Engineering, Genentech, Inc.  

  • A Two-In-One Antibody Against HER3 and EGFR has Superior Inhibitory Activity Compared with Monospecific Antibodies View Paper  
  • Variants of the Antibody Herceptin that Interact with HER2 and VEGF at the Antigen Binding Site View Paper  
  • High-Affinity Human Antibodies from Phage-Displayed Synthetic Fab Libraries with a Single Framework Scaffold View Paper  

Jason Baum, Ph.D., Principal Scientist, Research, Merrimack Pharmaceuticals, Inc.  

  • Rapid optimization and prototyping for therapeutic antibody-like molecules View Paper  

Nicolas Fischer, Ph.D., Head, Research, Novimmune SA  

  • Transferring the characteristics of naturally occurring and biased antibody repertoires to human antibody libraries by trapping CDRH3 sequences View Paper  
  • Deep sequencing of phage display libraries to support antibody discovery View Paper  

Alessandro Angelini, Ph.D., David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology  

  • Bicyclization and tethering to albumin yields long-acting peptide antagonists View Paper  
  • Chemical macrocyclization of peptides fused to antibody Fc fragments View Paper  
  • Bicyclic peptide inhibitor reveals large contact interface with a protease target View Paper  

Pavel Strop, Ph.D., Associate Research Fellow, Protein Engineering, Rinat-Pfizer, Inc.  

  • Location matters: Site of conjugation modulates stability and pharmacokinetics of antibody-drug-conjugates View Paper  
  • Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair View Paper  

Martine Piccart, M.D., Ph.D., Head, Medical Oncology, Jules Bordet Institute; Chair, ESMO  

  • Four-year results of a multicenter phase III trial comparing a full dose epirubicin-cyclophosphamide regimen with classical CMF and with a low dose pirubicincyclophosphamide regimen in the adjuvant therapy of node-positive pre and postmenopausal breast cancer patients View Paper  
  • A Randomized Trial of Trastuzumab following Adjuvant Chemotherapy in Women with HER2-Positive Breast Cancer View Paper  
  • Taxanes Alone or in Combination with Anthracyclines as First-Line Therapy of Patients with Metastatic Breast Cancer View Paper  

Development of Novel Biotherapeutics 

 

Hubert Kettenberger, Ph.D., Principal Scientist, Large Molecule Research, Roche Pharma Research and Early Development  

  • Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable Domain View Paper  
  • Progress in Overcoming the Chain Association Issue in Bispecific Heterodimeric IgG Antibodies View Paper  
  • Immunoglobulin Domain Crossover as a Generic Approach for the Production of Bispecific IgG Antibodies View Paper  

Bernhard Helk, Ph.D., Head, New Technologies, Biologics, Novartis Pharma AG  

  • Protein crystallization in stirred systems-Scale-up via the maximum local energy dissipation View Paper  
  • Fast and scalable purification of a therapeutic full-length antibody based on process crystallization View Paper  

Arieh Gertler, Ph.D., Professor, Institute of Biochemistry, Food Science and Nutrition, Hebrew University in Jerusalem  

  • Development and characterization of high affinity leptins and leptin antagonists View Paper  

Birgit Bossenmaier, Ph.D., Principle Scientist, Discovery Oncology, Roche  

  • A therapeutic antibody that binds the inactive HER3 receptor is optimized for immune effector activation View Paper  

Tariq Ghayur, Ph.D., Senior Research Fellow, DVD – Ig & Novel Biologics, Abbvie, Inc.  

  • Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule View Paper  
  • The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen View Paper 

Jonas V. Schaefer, Ph.D., High-Throughput Laboratory, Biochemistry, University of Zurich   

  • Engineering Aggregation Resistance in IgG by Two Independent Mechanisms: Lessons from Comparison of Pichia Pastoris and Mammalian Cell Expression  View Paper 
  • Transfer of Engineered Biophysical Properties between Different Antibody Formats and Expression Systems  View Paper